178 related articles for article (PubMed ID: 37676680)
1. Neoadjuvant Immune Checkpoint Inhibitor Therapy for Localized Deficient Mismatch Repair Colorectal Cancer: A Review.
Emiloju OE; Sinicrope FA
JAMA Oncol; 2023 Dec; 9(12):1708-1715. PubMed ID: 37676680
[TBL] [Abstract][Full Text] [Related]
2. Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer.
Veen T; Kanani A; Lea D; Søreide K
Cancer Immunol Immunother; 2023 Oct; 72(10):3135-3147. PubMed ID: 37528319
[TBL] [Abstract][Full Text] [Related]
3. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bM0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study.
Han K; Tang JH; Liao LE; Jiang W; Sui QQ; Xiao BY; Li WR; Hong ZG; Li Y; Kong LH; Li DD; Zhang XS; Pan ZZ; Steele SR; Ding PR
Dis Colon Rectum; 2023 Oct; 66(10):e996-e1005. PubMed ID: 35485833
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer.
Xiao BY; Zhang X; Cao TY; Li DD; Jiang W; Kong LH; Tang JH; Han K; Zhang CZ; Mei WJ; Xiao J; Pan ZZ; Li YF; Zhang XS; Ding PR
J Natl Compr Canc Netw; 2023 Jan; 21(1):60-66.e5. PubMed ID: 36630898
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Immune Checkpoint Inhibitor Therapy for Patients With Microsatellite Instability-High Colorectal Cancer: Shedding Light on the Future.
Sahin IH; Zhang J; Saridogan T; Gorantla V; Rhree J; Malhotra M; Thomas R; Hsu D; Saeed A
JCO Oncol Pract; 2023 May; 19(5):251-259. PubMed ID: 36862965
[TBL] [Abstract][Full Text] [Related]
7. Outcome of Patients With Early-Stage Mismatch Repair Deficient Colorectal Cancer Receiving Neoadjuvant Immunotherapy: A Systematic Review.
Chakrabarti S; Grewal US; Vora KB; Parikh AR; Almader-Douglas D; Mahipal A; Sonbol MBB
JCO Precis Oncol; 2023 Aug; 7():e2300182. PubMed ID: 37595183
[TBL] [Abstract][Full Text] [Related]
8. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
Marolleau P; Tougeron D; Allignet B; Cohen R; Sefrioui D; Gallet B; Dumont F; Guimbaud R; Alouani E; Passot G; Desolneux G; Ghiringhelli F; Marchal F; Mourthadhoi F; Coriat R; Desgrippes R; Locher C; Goujon G; Des Guetz G; Aparicio T; Paubelle E; Dupré A; de la Fouchardière C
Int J Cancer; 2023 Oct; 153(7):1376-1385. PubMed ID: 37403609
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.
Coutzac C; Bibeau F; Ben Abdelghani M; Aparicio T; Cohen R; Coquan E; Dubreuil O; Evesque L; Ghiringhelli F; Kim S; Lesourd S; Neuzillet C; Phelip JM; Piessen G; Rochigneux P; Samalin E; Soularue E; Touchefeu Y; Tougeron D; Zaanan A; de la Fouchardière C
Dig Liver Dis; 2022 Oct; 54(10):1335-1341. PubMed ID: 35907691
[TBL] [Abstract][Full Text] [Related]
10. Therapy with pembrolizumab in treatment-naïve patients with nonmetastatic, mismatch repair deficient colorectal cancer.
Eefsen RL; Larsen JS; Klarskov LL; Altaf R; Høgdall E; Ingeholm P; Lykke J; Nielsen DL; Pfeiffer P; Poulsen LØ; Qvortrup C; Schou JV; Mau-Sørensen M; Østerlind K; Jensen BV
Int J Cancer; 2023 May; 152(10):2145-2152. PubMed ID: 36594580
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
Zhang X; Yang R; Wu T; Cai X; Li G; Yu K; Li Y; Ding R; Dong C; Li J; Hu R; Feng Q; Li Y
Front Immunol; 2022; 13():913483. PubMed ID: 35958603
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer.
Kanani A; Veen T; Søreide K
Br J Surg; 2021 Dec; 108(12):1417-1425. PubMed ID: 34694371
[TBL] [Abstract][Full Text] [Related]
13. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
Front Immunol; 2022; 13():795972. PubMed ID: 35371084
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
André T; Cohen R; Salem ME
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
[TBL] [Abstract][Full Text] [Related]
16. Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade.
Jin Z; Sinicrope FA
J Clin Oncol; 2022 Aug; 40(24):2735-2750. PubMed ID: 35649217
[TBL] [Abstract][Full Text] [Related]
17. Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors.
Xie Y; Lin J; Zhang N; Wang X; Wang P; Peng S; Li J; Wu Y; Huang Y; Zhuang Z; Shen D; Zhu M; Liu X; Liu G; Meng X; Huang M; Yu H; Luo Y
J Natl Compr Canc Netw; 2023 Feb; 21(2):133-142.e3. PubMed ID: 36791752
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?
Zhu J; Lian J; Xu B; Pang X; Ji S; Zhao Y; Lu H
Front Immunol; 2023; 14():1120684. PubMed ID: 36949951
[TBL] [Abstract][Full Text] [Related]
19. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
